Study Finds Growing Stigma Around GLP-1 Weight‑Loss Drugs, Especially for White Women
Summary: As GLP-1 medications such as Ozempic and Wegovy become more widely used for weight loss, a new study from Georgetown University Medical Center shows an increase in social stigma toward people who use these drugs. The research demonstrates that women who lose weight with GLP-1 medications face greater judgment and social rejection than women who lose weight through diet and exercise. That stigma is largely driven by the belief that medication-assisted weight loss is an “easy way out,” and, unexpectedly, this “shortcut” bias was stronger when the woman in the scenario was portrayed as white.
Key Findings
- Racial differences in perceived stigma: Contrary to expectations, the study found higher levels of stigma when the woman described in the vignette was white rather than Black. White women who lost weight with GLP-1 medications were more likely to be accused of taking a shortcut and experienced greater social rejection.
- Shared assumptions across participants: The race of the study participants did not significantly change the effect; both Black and white participants tended to view GLP-1–assisted weight loss as a shortcut at similar rates.
- Widespread use, persistent shame: About 18% of U.S. adults have used or are using a GLP-1 drug, yet many report feeling shame and guilt driven by social narratives that delegitimize medication-assisted weight loss.
- Clinical consequences of stigma: Weight stigma is linked to increased stress, depression, anxiety and harmful health behaviors. Stigma may discourage many of the roughly 100 million Americans clinically eligible for these drugs from seeking evidence-based care.
Source: Georgetown University Medical Center
The study, published April 9 in the American Psychological Association’s journal Stigma & Health, explores how cultural narratives about “acceptable” ways to lose weight affect perceptions of women with obesity. Researchers found that when a woman’s weight loss was attributed to a GLP-1 medication, observers were more likely to express fat phobia, dislike, blame and a desire for social distance than when the same weight loss was described as the result of diet and exercise.
GLP-1 receptor agonists—medications commonly marketed under names such as Ozempic, Wegovy, Mounjaro and Zepbound—can offer clinically meaningful benefits for people with obesity. Still, many patients report feeling judged or ashamed for using these therapies, according to lead researcher Stacy Post, PhD, a social psychologist and postdoctoral researcher at Georgetown’s Lombardi Comprehensive Cancer Center.
“Our results show that the ‘easy way out’ perception does more than spark casual criticism,” Post said. “It can translate into measurable stigma that affects mental health and social relationships.” The study highlights how moralized beliefs about weight loss strategies can shape attitudes even when weight loss is substantial and health-oriented.
Study Design and Results
The researchers recruited 402 U.S. women, ages 30 to 49, who identified as Black or white and who reported being overweight or living with obesity. Participants were randomly assigned to read a vignette about a woman named Evette who lost 15% of her body weight either through diet and exercise or by using a GLP-1 medication. Evette was shown in a photograph that depicted her as either Black or white; the images were pre-tested to ensure visual parity.
After reading the vignette, participants rated Evette on stigma-related measures including fat phobia, dislike, blame, and desire for social distance, and reported whether they believed she had taken a weight-loss “shortcut.” Overall stigma scores were higher when weight loss was attributed to a GLP-1 drug. The researchers identified shortcut beliefs as a central mediating factor: perceiving medication-assisted weight loss as an easy way out predicted greater fat phobia, stronger dislike, more blame, and higher desire for social distance.
Unexpectedly, the effect of shortcut beliefs was stronger when Evette was portrayed as white. In other words, white women described as using GLP-1 medications drew more shortcut judgments and consequently more stigma than Black women in the same scenario. Participant race did not significantly moderate these effects, suggesting that assumptions about GLP-1s as a shortcut operate broadly across different observer groups.
Health Implications and Recommendations
Weight stigma is not merely an interpersonal problem; it has concrete health consequences. Experiences of stigma are associated with elevated stress, greater symptoms of depression and anxiety, and behavioral responses that can undermine long-term health. Stigma may also deter people from seeking or continuing evidence-based treatments for obesity.
The study authors recommend public communication strategies that explain the biological mechanisms of GLP-1 medications, emphasize their positive health outcomes, and challenge the perception that medication-assisted weight loss is inherently less legitimate than lifestyle changes. Reframing the conversation from moral judgments about willpower to evidence-based explanations about biology and health could reduce shame and help people access appropriate care.
Key Questions Answered
Q: Why was there more stigma toward white women using these drugs?
A: The researchers propose that observers held stronger shortcut assumptions when the weight-loss patient was depicted as white. Those shortcut beliefs directly predicted higher levels of dislike and blame in the scenarios featuring white women.
Q: Does the “shortcut” label affect health outcomes?
A: Yes. Feeling shamed for using medication can lead people to stop treatment, avoid medical care, or experience worsening mental health—outcomes that can offset the physical benefits of weight loss.
Q: How can this perception be changed?
A: The authors advocate shifting public messaging from a focus on willpower to a focus on biology and clinical evidence. Clear explanations of how GLP-1s work and why they are legitimate medical options can reduce moralizing judgments and stigma.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by editorial staff.
About this research
Author: Karen Teber
Source: Georgetown University Medical Center
Contact: Karen Teber – Georgetown University Medical Center
Image credit: Neuroscience News
Original Research: Social Perceptions of GLP-1–assisted Weight Loss in Black and White Women with Obesity by Post, S. M., Stock, M. L., & Persky, S., published in Stigma and Health. DOI: 10.1037/sah0000689. (Closed access)
Abstract (condensed)
This experimental study tested how exposure to different weight loss methods affected stigma toward a Black or White woman with obesity and whether participant race influenced those responses. A sample of 402 Black and White women with overweight or obesity read about a woman named Evette who lost 15% of her weight via diet/exercise or a GLP-1 medication. Participants reported stigmatizing attitudes and beliefs that Evette took a shortcut. Results showed greater stigma when weight loss was attributed to a GLP-1 drug and, contrary to expectations, when Evette was depicted as White. Shortcut beliefs mediated the relationship between GLP-1 use and stigma. Participant race did not significantly alter the mediated effects. The findings underscore the need to challenge societal narratives about what constitutes acceptable weight-loss strategies to reduce stigma and protect long-term health.